SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+20.31%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$754M
AUM Growth
+$754M
(+25%)
Cap. Flow
+$14.4M
Cap. Flow
% of AUM
1.91%
Top 10 Holdings %
Top 10 Hldgs %
48.98%
Holding
104
New
23
Increased
22
Reduced
27
Closed
20
Top Buys
| 1 |
Sanofi
SNY
|
$22.1M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$21.3M |
| 3 |
Novartis
NVS
|
$18.9M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$11.4M |
| 5 |
Viatris
VTRS
|
$11.3M |
Top Sells
| 1 |
ARQL
Arqule Inc
ARQL
|
$35.6M |
| 2 |
CELG
Celgene Corp
CELG
|
$24.8M |
| 3 |
Sarepta Therapeutics
SRPT
|
$13.9M |
| 4 |
Gilead Sciences
GILD
|
$13M |
| 5 |
Bristol-Myers Squibb
BMY
|
$12.5M |
Sector Composition
| 1 | Healthcare | 84.32% |
| 2 | Technology | 10.06% |
| 3 | Industrials | 1.58% |
| 4 | Consumer Discretionary | 1.5% |
| 5 | Communication Services | 0.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Johnson & Johnson
JNJ
$427B
| $64M | 5.27% | 438,653 +38,653 | +10% | +$5.64M |
|
|
2
Bristol-Myers Squibb
BMY
$96B
| $58.7M | 4.84% | 915,000 -194,900 | -18% | -$12.5M |
|
|
3
Sanofi
SNY
$121B
| $57.2M | 4.72% | 1,140,000 +440,000 | +63% | +$22.1M |
|
4
Merck
MRK
$210B
| $50.5M | 4.16% | 555,000 +85,000 | +18% | +$7.73M |
|
5
Novo Nordisk
NVO
$251B
| $37M | 3.05% | 640,000 +190,000 | +42% | +$11M |
|
6
Amicus Therapeutics
FOLD
$2.34B
| $27.3M | 2.25% | 2,800,320 -130,000 | -4% | -$1.27M |
|
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $21.3M | 1.75% | +251,382 | New | +$21.3M |
|
|
8
Novartis
NVS
$245B
| $18.9M | 1.56% | +200,000 | New | +$18.9M |
|
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $18.1M | 1.49% | 140,000 -108,038 | -44% | -$13.9M |
|
10
Verint Systems
VRNT
$1.23B
| $16.1M | 1.33% | 290,699 +156,210 | +116% | +$8.65M |
|
|
11
Acadia Pharmaceuticals
ACAD
$4.38B
| $15.3M | 1.26% | 357,000 +267,000 | +297% | +$11.4M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $12.5M | 1.03% | 115,713 -50,000 | -30% | -$5.41M |
|
|
13
Viatris
VTRS
$12.3B
| $11.3M | 0.93% | +560,000 | New | +$11.3M |
|
14
PTC Therapeutics
PTCT
$3.92B
| $10.3M | 0.85% | 214,736 -95,264 | -31% | -$4.58M |
|
15
Ascendis Pharma
ASND
$11.8B
| $10.3M | 0.85% | 73,773 | – | – |
|
16
uniQure
QURE
$896M
| $10M | 0.82% | 139,514 -37,986 | -21% | -$2.72M |
|
17
Microsoft
MSFT
$3.77T
| $9.26M | 0.76% | 58,741 +5,000 | +9% | +$788K |
|
|
BPMC
18
DELISTED
Blueprint Medicines
BPMC
| $8.49M | 0.7% | 106,000 +63,500 | +149% | +$5.09M |
|
19
Exicure
XCUR
$35.4M
| $8.26M | 0.68% | 2,888,888 +250,900 | +10% | +$718K |
|
20
Allot
ALLT
$362M
| $8.25M | 0.68% | 970,666 +309,635 | +47% | +$2.63M |
|
21
Rocket Pharmaceuticals
RCKT
$354M
| $8.24M | 0.68% | 361,888 -298,112 | -45% | -$6.79M |
|
22
Arvinas
ARVN
$568M
| $8.17M | 0.67% | 198,781 -6,500 | -3% | -$267K |
|
|
GWPH
23
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $8.05M | 0.66% | 77,000 +3,000 | +4% | +$314K |
|
24
ProQR Therapeutics
PRQR
$237M
| $7.98M | 0.66% | 805,000 -110,000 | -12% | -$1.09M |
|
25
AudioCodes
AUDC
$273M
| $7.86M | 0.65% | 306,053 -22,210 | -7% | -$571K |
|